#United States #New York #REGENXBIO #RGX-111 #Stephen Pakola

Stephen Pakola's Role Under Scrutiny in RGX-111 Safety Allegations

On March 18, 2026, it was reported that Dr. Stephen Pakola, the Chief Medical Officer and Executive Vice President of REGENXBIO, has been named in a securities class action lawsuit. This lawsuit stems from claims that he allegedly misled investors about the safety profiles of RGX-111, a gene therapy aimed at treating severe Mucopolysaccharidosis Type I (MPS I).

Background of the Case

The controversy began when investors were reportedly assured by Dr. Pakola that RGX-111 was “well-tolerated” without any serious drug-related adverse events. These statements were made during various press releases and earnings calls between February 2022 and November 2023. Such reassurances led to heightened investor confidence, ultimately affecting the company's stock price significantly.

However, the situation took a turn on January 28, 2026, when it was revealed that significant safety risks associated with RGX-111 had either been understated or completely ignored. Following this revelation, the share price plummeted by $2.40, marking a startling 17.8% drop in value and closing at $11.01. This swift decline sparked a wave of dissatisfaction among investors and led to the current legal fallout.

The Claims Against Dr. Pakola

The lawsuit identifies statements made by Dr. Pakola concerning the RGX-111 therapy. These declarations emphasized the treatment's favorable outcomes and omitted pertinent information regarding its safety risks. For instance:

• - On February 9, 2022, Dr. Pakola proclaimed there were “no drug-related serious adverse events” during the RGX-111 Phase I/II trial, along with “encouraging” biomarker data.
• - During the earnings call on February 28, 2023, he reiterated that the therapy was “well tolerated.”
• - Again, on May 3, 2023, he mentioned it was “well tolerated in 8 patients.”
• - By November 8, 2023, he acknowledged the de-prioritization of RGX-111 but maintained an optimistic outlook about seeking “strategic alternatives.”

Dr. Pakola's continuing assurance of RGX-111’s safety, despite possessing information about potential CNS neoplasms, reflects a troubling disconnect between public communication and private knowledge.

Legal Implications

Legal experts suggest that Dr. Pakola's role as a senior officer grants him significant responsibility regarding the truthfulness of disclosures made about clinical programs. Under Section 20(a) of the Securities Exchange Act, he could be held liable as a controlling person. This provision underscores the importance of accuracy in communications made by executives who are privy to sensitive clinical data.

Joseph E. Levi, a principal attorney at Levi & Korsinsky, LLP, weighed in on the case, stating, "When the executive responsible for clinical programs repeatedly assures investors that a therapy is well-tolerated while material safety risks allegedly remain undisclosed, accountability must follow."

What Lies Ahead

For investors affected by this case, the deadline to become a lead plaintiff is set for April 14, 2026. Individuals claiming losses due to the alleged misrepresentations may seek recourse through legal channels.

Furthermore, Levi & Korsinsky, LLP, recognized as a leading firm in securities litigation, is actively pursuing claims on behalf of affected investors.

This case serves as a pivotal moment for transparency in the biotechnology sector, emphasizing the need for clarity in clinical trial communications. As the legal proceedings unfold, investors closely watch how accountability is determined in the face of potentially damaging assurances.

Conclusion

Dr. Pakola's situation reflects a broader concern within the biotech industry: the fine line between positive corporate messaging and the ethical obligation to disclose all relevant information to investors. The outcomes of this litigation could not only impact REGENXBIO's future but also set important precedents for investor protections in the biotech landscape.